Insider Purchases: Inside the Buy
Tag: Funanc1al Investing
SSP Stock Analysis 2026: Scripps Insiders Double Down on a High-Stakes Media Turnaround
When insiders start buying stock aggressively, investors take notice. In early 2026, executives, directors, and members of the Scripps family all stepped in to buy SSP shares. The question now: is this a deep-value media turnaround or a value trap?
CSX Stock Analysis 2026: New CEO’s $1M Bet vs. Valuation Red Flags
A new CEO buying $1M in shares is always interesting. But with CSX trading near all-time highs while earnings soften, investors face a classic dilemma: operational confidence vs valuation discipline.
SOFI Stock Analysis 2026: CEO Insider Buys, Crypto Ambition, and the Path to $30
SoFi just delivered its first billion-dollar quarter, record member growth, and a fresh insider buy from CEO Anthony Noto. The fintech story is evolving from speculative startup to profitable platform — but valuation and skepticism remain. Here’s the FUNanc1al breakdown of the opportunity.
NOW Stock Analysis 2026: Bill McDermott’s $3M “Strong Buy” Signal — Is ServiceNow the AI Control Tower?
ServiceNow (NOW) is fighting a valuation reset with AI-powered fundamentals. CEO Bill McDermott just made a rare $3M insider buy — a signal worth decoding.
FOUR Stock Analysis 2026: Is Shift4 a Payments Powerhouse or a Falling Knife?
Shift4 (FOUR) is a full-blown battleground stock. Founder buying, 35% short interest, heavy institutional ownership, and a forward P/E near 7. Rocket fuel — or engine trouble?
PODD Stock Analysis 2026: Is Insulet the Ultimate Growth Play or a Valuation Trap?
Insulet (PODD) just delivered 31% revenue growth and insiders are buying — yet the stock trades at 70x earnings. Is this premium medtech compounder a long-term winner or priced for perfection? Here’s the FUNanc1al breakdown.
AbCellera (ABCL) Stock Analysis: 7 Triggers for a Biotech Short Squeeze or Long-Term Multibagger?
Down 95%, heavily shorted, yet sitting on $700M in liquidity and insider conviction — AbCellera (ABCL) may be biotech’s ultimate asymmetric bet.
Hamilton Lane (HLNE) 2026 Deep Dive: Inside the $4M Insider Buy and Private Market Growth
$4M+ in insider buys. 18% revenue growth. Private markets expanding. Hamilton Lane may be a premium compounder trading 47% below its highs.
POOL Stock Analysis 2026: Why Insiders & Buffett Are Diving In
Insiders are buying, Buffett is in, shorts are nervous—and POOL is 63% off its highs. A deep dive into the maintenance moat behind this backyard empire.
Vertex (VERX) Stock: Founder "Re-Entry" & The AI Tax Pivot 2026
Vertex (VERX) isn’t flashy—but it’s mission-critical. With the founder buying back shares, institutions owning more than the float, and an AI + e-invoicing pivot underway, this “boring” SaaS might be setting up a very interesting comeback.
Quick links
Search
Privacy Policy
Refund Policy
Shipping Policy
Terms of Service
Contact us
About us
FUNanc!al distills the fun in finance and the finance in fun, makes news personal, and helps all reach happiness.
